Concept Medical announces index patient enrolment in world's first Randomized Controlled Trial with Sirolimus Coated Balloon for the treatment of Superficial Femoral Artery (SFA) in Peripheral Artery Disease

Food and Healthcare Press Releases Tuesday September 15, 2020 10:51
SINGAPORE--15 Sep--PRNewswire/InfoQuest

Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE SFA (Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in The TrEatment of Superficial Femoral Artery and Popliteal Artery Disease).

The index patient was successfully enrolled on 11th September in Singapore.

FUTURE SFA is a randomized, double blind, placebo-controlled, multi-center trial to determine the effectiveness of MagicTouch PTA sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal arterial disease.

The burden of peripheral arterial disease (PAD) is high globally. Its burden is likely to grow in the coming years given the rising trends in key risk factors such as age and diabetes. In its most advanced stage, patients present as critical limb ischemia (CLI) and many end up with leg amputations.

Current standard of care for severe PAD is revascularization, the majority of which involves the use of balloon angioplasty to unblock the vessel and restore blood flow to the leg. However, these vessels frequently become blocked again, resulting in repeated procedures which is potentially dangerous and may result in loss of limb or even life.

Local drug delivery using drug coated balloons (DCBs) during angioplasty can successfully deliver anti-proliferative drugs to the lesions in the artery, with the aim of keeping the vessel open for longer. Sirolimus coated balloons are considered to be the next new generation of DCBs and the novel MagicTouch PTA sirolimus coated balloon (SCB), has emerged as one of the most promising transcatheter technologies in preventing restenosis for diseased arteries.

The principal investigator of FUTURE-SFA is Associate Professor Edward Choke from the Department of General Surgery (Vascular Surgery) at the Sengkang General Hospital, Singapore.

Associate Professor Edward Choke said, "I am inspired by the bold, imaginative and futuristic concepts presented by the Nanolute technology of the MagicTouch PTA sirolimus coated balloon. In contrast to other contemporary technologies, MagicTouch PTA offers a solution which optimizes both the deliverability and the absorption of sirolimus into the vessel wall."

He added, "Initial experience with the XTOSI first in man study suggested that MagicTouch PTA can provide an effective way of revascularization for PAD patients, by keeping the vessels open longer and reducing the need of repeated angioplasty procedures. I look forward to the FUTURE-SFA randomized controlled trial, which will test whether the Magic Touch PTA sirolimus coated balloon can improve the patencies of femoral and popliteal arteries in PAD patients. We hope to establish whether SCB will emerge as the new standard of care which will impact the way we treat PAD."

The trial will enrol 153 patients with Rutherford class 3 to 6 PAD. These subjects will be randomized in 2:1 fashion to receive either Magic Touch PTA or standard balloon angioplasty.
Primary outcome will be primary patency at 6 months, defined as duplex peak systolic velocity ratio (PSVR) of 2.4 or less.

The trial is designed to follow a rigorous blinding protocol in order to minimise bias. Patients, care providers, investigators and outcome assessors, including vascular technologists performing the duplex ultrasound, will be blinded to the treatment allocations. The patients will be followed up for two years.

[NCT04511234 - Randomized Controlled Trial of First Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in The Treatment of Superficial Femoral Artery and Popliteal Artery Disease (FUTURE-SFA)]
www.conceptmedical.com
Photo: https://mma.prnewswire.com/media/1273493/Future_SFA_Enrollment.jpg
Logo: https://mma.prnewswire.com/media/1244676/Concept_Medical_Logo.jpg

Latest Press Release

Doctor Anywhere launches online mental health consultation service in the region

Doctor Anywhere, a tech-enabled omni-channel healthcare provider with operations in Southeast Asia, launched an online mental health video consultation service. This is in addition to a suite of other tele-health services including doctor consultation...

FDI World Dental Federation says Be Proud of Your Mouth for World Oral Health Day 2021 to 2023

Representing more than one million dentists worldwide, FDI World Dental Federation (FDI) unveils its three-year "Be Proud of Your Mouth" World Oral Health Day campaign. World Oral Health Day (WOHD) is celebrated globally every year on 20 March. Its...

One broken bone leads to another, warns IOF on World Osteoporosis Day

Today, the International Osteoporosis Foundation (IOF) calls for all adults to be alert to their risk factors for osteoporosis, a disease which can lead to a dangerous, life-threatening spiral of broken bones. A broken bone (known as a fracture) which...

MED-EL: First Surgeries Ever in Europe with a Totally Implantable Cochlear Implant

Leading hearing implant manufacturer MED-EL sets another revolutionary milestone in its long-standing history of technological innovations. On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI). It was...

Roche paves way for a new era of HCC treatment

Roche, the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics, led by Farid Bidgoli (3rd from right), General Manager, Roche Thailand, Myanmar, Cambodia and Laos, along with Saranond Assavavipapan (Left),...

Related Topics